Immunologic Therapeutic Interventions in Asthma. Impact on Natural History

Clinics in Chest Medicine

Volumn 33, Issue 3, 2012, Pages 585-597

  Bourdin, Arnaud ^a,b   Humbert, Marc ^c   Chanez, Pascal ^d  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b INSERM   (France)

^c Universite Paris Sud   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Asthma; Immunology; Therapeutic intervention

Indexed keywords

ALTRAKINCEPT; ANRUKINZUMAB; BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LEBRIKIZUMAB; MEPOLIZUMAB; MOGAMULIZUMAB; NAVARIXIN; OMALIZUMAB; PASCOLIZUMAB; PITRAKINRA; PLACEBO; RESLIZUMAB; TACROLIMUS; TRALOKINUMAB;

AIRWAY REMODELING; ASTHMA; ATOPIC DERMATITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; DRUG TARGETING; EOSINOPHIL COUNT; HUMAN; NONHUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TH17 CELL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ASTHMA; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MOLECULAR TARGETED THERAPY; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84865558388     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.06.004     Document Type: Review

References (139)

1. Grainge C.L., Lau L.C., Ward J.A., et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011, 364(21):2006-2015.
2. Thamrin C., Zindel J., Nydegger R., et al. Predicting future risk of asthma exacerbations using individual conditional probabilities. J Allergy Clin Immunol 2011, 127(6):1494-1502, e3.
3. Lange P., Parner J., Vestbo J., et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998, 339(17):1194-1200.
4. Vignola A.M., Chanez P., Bonsignore G., et al. Structural consequences of airway inflammation in asthma. J Allergy Clin Immunol 2000, 105(2 Pt 2):S514-S517.
5. Godard P., Chanez P., Siraudin L., et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002, 19(1):61-67.
6. Strachan D.P., Griffiths J.M., Johnston I.D., et al. Ventilatory function in British adults after asthma or wheezing illness at ages 0-35. Am J Respir Crit Care Med 1996, 154(6 Pt 1):1629-1635.
7. Roorda R.J., Gerritsen J., van Aalderen W.M., et al. Follow-up of asthma from childhood to adulthood: influence of potential childhood risk factors on the outcome of pulmonary function and bronchial responsiveness in adulthood. J Allergy Clin Immunol 1994, 93(3):575-584.
8. Suissa S., Ernst P., Benayoun S., et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000, 343(5):332-336.
9. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004, 170(8):836-844.
10. Bateman E.D., Bousquet J., Busse W.W., et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma Control (GOAL) study. Allergy 2008, 63(7):932-938.
11. Rabe K.F., Vermeire P.A., Soriano J.B., et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000, 16(5):802-807.
12. Godard P., Huas D., Sohier B., et al. Presse Med 2005, 34(19 Pt 1):1351-1357. [in French].
13. Chanez P., Godard P. Is difficult asthma still clinically meaningful?. Eur Respir J 2006, 28(5):897-899.
14. Chanez P., Wenzel S.E., Anderson G.P., et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol 2007, 119(6):1337-1348.
15. Salmeron S., Liard R., Elkharrat D., et al. Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet 2001, 358(9282):629-635.
16. van der Merwe L., de Klerk A., Kidd M., et al. Case-control study of severe life threatening asthma (SLTA) in a developing community. Thorax 2006, 61(9):756-760.
17. Lanes S.F., Lanza L.L., Wentworth C.E. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998, 158(3):857-861.
18. Turner M.O., Noertjojo K., Vedal S., et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1804-1809.
19. Chung K.F., Godard P., Adelroth E., et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS task force on difficult/therapy-resistant asthma. European Respiratory Society. Eur Respir J 1999, 13(5):1198-1208.
20. Bel E.H., Sousa A., Fleming L., et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011, 66(10):910-917.
21. Frey U., Maksym G., Suki B. Temporal complexity in clinical manifestations of lung disease. J Appl Physiol 2011, 110(6):1723-1731.
22. Stern G., de Jongste J., van der Valk R., et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol 2011, 128(2):293-300.
23. Ernst P. Inhaled corticosteroids moderate lung function decline in adults with asthma. Thorax 2006, 61(2):93-94.
24. Heaney L.G., Robinson D.S. Severe asthma treatment: need for characterising patients. Lancet 2005, 365(9463):974-976.
25. Haldar P., Pavord I.D., Shaw D.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178(3):218-224.
26. Moore W.C., Meyers D.A., Wenzel S.E., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181(4):315-323.
27. Lemiere C., Ernst P., Olivenstein R., et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006, 118(5):1033-1039.
28. Green R.H., Brightling C.E., McKenna S., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360(9347):1715-1721.
29. Colavita A.M., Reinach A.J., Peters S.P. Contributing factors to the pathobiology of asthma. The Th1/Th2 paradigm. Clin Chest Med 2000, 21(2):263-277.
30. Magnan A.O., Mely L.G., Camilla C.A., et al. Assessment of the Th1/Th2 paradigm in whole blood in atopy and asthma. Increased IFN-gamma-producing CD8(+) T cells in asthma. Am J Respir Crit Care Med 2000, 161(6):1790-1796.
31. Holt P.G., Macaubas C., Stumbles P.A., et al. The role of allergy in the development of asthma. Nature 1999, 402(Suppl 6760):B12-B17.
32. Corren J., Lemanske R.F., Hanania N.A., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2008, 365(12):1088-1098.
33. Zhou B., Comeau M.R., De Smedt T., et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 2005, 6(10):1047-1053.
34. Allakhverdi Z., Comeau M.R., Jessup H.K., et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007, 204(2):253-258.
35. Seshasayee D., Lee W.P., Zhou M., et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest 2007, 117(12):3868-3878.
36. Ziegler S.F., Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 2010, 11(4):289-293.
37. Xiao C., Puddicombe S.M., Field S., et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011, 128(3):549-556.e1-12.
38. Maeda Y., Chen G., Xu Y., et al. Airway epithelial transcription factor NK2 homeobox 1 inhibits mucous cell metaplasia and Th2 inflammation. Am J Respir Crit Care Med 2011, 184(4):421-429.
39. Chanez P. Severe asthma is an epithelial disease. Eur Respir J 2005, 25(6):945-946.
40. Siracusa M.C., Saenz S.A., Hill D.A., et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 2011, 477(7363):229-233.
41. Munitz A., Brandt E.B., Mingler M., et al. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A 2008, 105(20):7240-7245.
42. Corry D.B., Kheradmand F. Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma. Am J Respir Med 2002, 1(3):185-193.
43. Holgate S.T. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches?. J Allergy Clin Immunol 2011, 128(3):495-505.
44. Barnes P.J. Cytokine-directed therapies for asthma. J Allergy Clin Immunol 2001, 108(Suppl 2):S72-S76.
45. Jiang H., Harris M.B., Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000, 105(6 Pt 1):1063-1070.
46. Corry D.B., Kheradmand F. Induction and regulation of the IgE response. Nature 1999, 402(Suppl 6760):B18-B23.
47. Borish L.C., Nelson H.S., Corren J., et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107(6):963-970.
48. Borish L.C., Nelson H.S., Lanz M.J., et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160(6):1816-1823.
49. Hart T.K., Blackburn M.N., Brigham-Burke M., et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002, 130(1):93-100.
50. Wenzel S., Wilbraham D., Fuller R., et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370(9596):1422-1431.
51. Woodruff P.G., Boushey H.A., Dolganov G.M., et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 2007, 104(40):15858-15863.
52. Wynn T.A. IL-13 effector functions. Annu Rev Immunol 2003, 21:425-456.
53. Kuperman D.A., Huang X., Koth L.L., et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002, 8(8):885-889.
54. Grunig G. IL-13 and adenosine: partners in a molecular dance?. J Clin Invest 2003, 112(3):329-331.
55. Zhu Z., Homer R.J., Wang Z., et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103(6):779-788.
56. Gauvreau G.M., Boulet L.P., Cockcroft D.W., et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011, 183(8):1007-1014.
57. Busse W.W., Ring J., Huss-Marp J., et al. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010, 125(4):803-813.
58. Bousquet J., Chanez P., Lacoste J.Y., et al. Eosinophilic inflammation in asthma. N Engl J Med 1990, 323(15):1033-1039.
59. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167(2):199-204.
60. Flood-Page P., Menzies-Gow A., Phipps S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112(7):1029-1036.
61. Menzies-Gow A.N., Flood-Page P.T., Robinson D.S., et al. Effect of inhaled interleukin-5 on eosinophil progenitors in the bronchi and bone marrow of asthmatic and non-asthmatic volunteers. Clin Exp Allergy 2007, 37(7):1023-1032.
62. Romagnoli M., Vachier I., Tarodo de la Fuente P., et al. Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J 2002, 20(6):1370-1377.
63. Flood-Page P., Swenson C., Faiferman I., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176(11):1062-1071.
64. O'Byrne P.M. The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007, 176(11):1059-1060.
65. Wenzel S.E. Eosinophils in asthma-closing the loop or opening the door?. N Engl J Med 2009, 360(10):1026-1028.
66. Nair P., Pizzichini M.M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360(10):985-993.
67. Haldar P., Brightling C.E., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360(10):973-984.
68. Smith A.D., Cowan J.O., Brassett K.P., et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352(21):2163-2173.
69. Roufosse F., de Lavareille A., Schandene L., et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126(4):828-835.e3.
70. Boulware D.R., Stauffer W.M., Walker P.F. Hypereosinophilic syndrome and mepolizumab. N Engl J Med 2008, 358(26):2839.
71. Rothenberg M.E., Klion A.D., Roufosse F.E., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358(12):1215-1228.
72. ten Brinke A., Zwinderman A.H., Sterk P.J., et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001, 164(5):744-748.
73. ten Brinke A., Zwinderman A.H., Sterk P.J., et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004, 170(6):601-605.
74. Castro M., Mathur S., Hargreave F., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184(10):1125-1132.
75. Gevaert P., Lang-Loidolt D., Lackner A., et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006, 118(5):1133-1141.
76. Ogbogu P.U., Bochner B.S., Butterfield J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124(6):1319-1325.e3.
77. Seale J.P. European Respiratory Society (ERS) - 20th Annual Congress. IDrugs 2010, 13(11):762-764.
78. Busse W.W., Katial R., Gossage D., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010, 125(6):1237-1244.e2.
79. Kolbeck R., Kozhich A., Koike M., et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010, 125(6):1344-1353.e2.
80. Nicolaides N.C., Holroyd K.J., Ewart S.L., et al. Interleukin 9: a candidate gene for asthma. Proc Natl Acad Sci U S A 1997, 94(24):13175-13180.
81. Longphre M., Li D., Gallup M., et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest 1999, 104(10):1375-1382.
82. Cheng G., Arima M., Honda K., et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 2002, 166(3):409-416.
83. Kearley J., Erjefalt J.S., Andersson C., et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med 2011, 183(7):865-875.
84. Tunon-de-Lara J.M., Berger P., Marthan R. Chymase-positive mast cells: a double-edged sword in asthma?. Am J Respir Crit Care Med 2005, 172(5):647-648.
85. Antoniu S.A. MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther 2010, 12(2):233-239.
86. Parker J.M., Oh C.K., LaForce C., et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011, 11:14.
87. Humbert M., de Blay F., Garcia G., et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009, 64(8):1194-1201.
88. Kitaura M., Nakajima T., Imai T., et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 1996, 271(13):7725-7730.
89. Ochi H., Hirani W.M., Yuan Q., et al. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999, 190(2):267-280.
90. Humbles A.A., Lu B., Friend D.S., et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A 2002, 99(3):1479-1484.
91. Allakhverdi Z., Allam M., Guimond A., et al. Multitargeted approach using antisense oligonucleotides for the treatment of asthma. Ann N Y Acad Sci 2006, 1082:62-73.
92. Gauvreau G.M., Boulet L.P., Cockcroft D.W., et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177(9):952-958.
93. Humbert M., Beasley R., Ayres J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60(3):309-316.
94. Wahn U., Martin C., Freeman P., et al. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009, 64(12):1780-1787.
95. Grundmann S.A., Hemfort P.B., Luger T.A., et al. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 2008, 121(1):257-258.
96. Saini S., Rosen K.E., Hsieh H.J., et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011, 128(3):567-573.e1.
97. Pinto J.M., Mehta N., DiTineo M., et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010, 48(3):318-324.
98. Campbell J.D., Spackman D.E., Sullivan S.D. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010, 65(9):1141-1148.
99. Sullivan S.D., Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008, 63(6):670-684.
100. Revicki D., Brown R., Dale P. Questioning the economic evaluation of omalizumab. J Allergy Clin Immunol 2008, 121(6):1514.
101. Busse W.W., Morgan W.J., Gergen P.J., et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011, 364(11):1005-1015.
102. Slavin R.G., Ferioli C., Tannenbaum S.J., et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009, 123(1):107-113.e3.
103. Nopp A., Johansson S.G., Adedoyin J., et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010, 65(1):56-60.
104. Walker S., Monteil M., Phelan K., et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, 2. CD003559.
105. Bousquet J., Wenzel S., Holgate S., et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004, 125(4):1378-1386.
106. Humbert M., Durham S.R., Ying S., et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996, 154(5):1497-1504.
107. Humbert M., Durham S.R., Kimmitt P., et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 1997, 99(5):657-665.
108. Ying S., Humbert M., Barkans J., et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997, 158(7):3539-3544.
109. Humbert M., Corrigan C.J., Kimmitt P., et al. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997, 156(3 Pt 1):704-708.
110. Ying S., Humbert M., Meng Q., et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol 2001, 107(4):686-692.
111. Takhar P., Corrigan C.J., Smurthwaite L., et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007, 119(1):213-218.
112. Balzar S., Strand M., Rhodes D., et al. IgE expression pattern in lung: relation to systemic IgE and asthma phenotypes. J Allergy Clin Immunol 2007, 119(4):855-862.
113. Humbert M., Menz G., Ying S., et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999, 20(11):528-533.
114. Mouthuy J., Detry B., Sohy C., et al. Presence in sputum of functional dust mite-specific IgE antibodies in intrinsic asthma. Am J Respir Crit Care Med 2011, 184(2):206-214.
115. Corrigan C.J. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med 2002, 1(1):47-54.
116. Virtanen H., Remitz A., Malmberg P., et al. Topical tacrolimus in the treatment of atopic dermatitis-does it benefit the airways? A 4-year open follow-up. J Allergy Clin Immunol 2007, 120(6):1464-1466.
117. Kawano T., Matsuse H., Kondo Y., et al. Tacrolimus reduces urinary excretion of leukotriene E(4) and inhibits aspirin-induced asthma to threshold dose of aspirin. J Allergy Clin Immunol 2004, 114(6):1278-1281.
118. Stevenson D.D., Mehra P.K., White A.A., et al. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2005, 116(4):755-760.
119. Lock S.H., Kay A.B., Barnes N.C. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996, 153(2):509-514.
120. Nizankowska E., Soja J., Pinis G., et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995, 8(7):1091-1099.
121. Alexander A.G., Barnes N.C., Kay A.B., et al. Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations. Eur Respir J 1995, 8(4):574-578.
122. Alexander A.G., Barnes N.C., Kay A.B. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992, 339(8789):324-328.
123. Evans D.J., Cullinan P., Geddes D.M. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001, 2. CD002993.
124. Marin M.G. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Chest 1997, 112(1):29-33.
125. Neill D.R., Wong S.H., Bellosi A., et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464(7293):1367-1370.
126. Howarth P.H., Babu K.S., Arshad H.S., et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60(12):1012-1018.
127. Erin E.M., Leaker B.R., Nicholson G.C., et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006, 174(7):753-762.
128. Morjaria J.B., Chauhan A.J., Babu K.S., et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008, 63(7):584-591.
129. Berry M.A., Hargadon B., Shelley M., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354(7):697-708.
130. Holgate S.T., Noonan M., Chanez P., et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011, 37(6):1352-1359.
131. Wenzel S.E., Barnes P.J., Bleecker E.R., et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179(7):549-558.
132. Pignatti P., Moscato G., Casarini S., et al. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways. J Allergy Clin Immunol 2005, 115(1):88-94.
133. Todd C.M., Murphy D.M., Watson R.M., et al. Treatment with the CXCR2 antagonist SCH527123 reduced neutrophil levels in blood and airways but not bone marrow in mild asthmatic subjects. Am J Respir Crit Care Med 2010, 181:A4237.
134. McKinley L., Alcorn J.F., Peterson A., et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008, 181(6):4089-4097.
135. Kawaguchi M., Adachi M., Oda N., et al. IL-17 cytokine family. J Allergy Clin Immunol 2004, 114(6):1265-1273. [quiz: 1274].
136. Park K.S., Korfhagen T.R., Bruno M.D., et al. SPDEF regulates goblet cell hyperplasia in the airway epithelium. J Clin Invest 2007, 117(4):978-988.
137. Hirota T., Takahashi A., Kubo M., et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. Nat Genet 2011, 43(9):893-896.
138. Torgerson D.G., Ampleford E.J., Chiu G.Y., et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet 2011, 43(9):887-892.
139. Xirakia C., Koltsida O., Stavropoulos A., et al. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010, 181(11):1207-1216.